MDR1 siRNA对胰腺癌细胞株BxPC-3耐药性影响的实验研究  

Effect of MDR1 siRNA on drug resistance of pancreatic cancer cell line BxPC-3

作　　者：徐近[1] 虞先浚[1] 龙江[1] 金忱[1] 傅德良[1] 倪泉兴[1] 

机构地区：[1]复旦大学附属华山医院外科复旦大学胰腺病研究所,上海200040

出　　处：《外科理论与实践》2009年第1期43-45,共3页Journal of Surgery Concepts & Practice

基　　金：国家自然科学基金(30672057)

摘　　要：目的:观察阻断多药耐药基因1(MDR1)表达后胰腺癌细胞对化疗药物敏感性的变化,探索提高胰腺癌化疗疗效的新方法。方法:采用RNA干扰技术,构建MDR1 siRNA重组质粒,脂质体介导转染人胰腺癌细胞株BxPC-3,并筛选稳定转染细胞克隆,RT-PCR和Western印迹法检测MDR1 mRNA和蛋白的表达变化。将细胞接种于裸鼠,观察移植瘤对化疗药物吉西他滨敏感性的变化。结果:转染MDR1 siRNA质粒后胰腺癌细胞株BxPC-3MDR1 mRNA与蛋白表达水平明显降低。体内实验结果显示,将转染前后的细胞接种于裸鼠,转染组移植瘤对化疗药物吉西他滨更为敏感(P<0.05)。结论:通过RNA干扰技术,可在转录和翻译水平降低MDR1在胰腺癌细胞株BxPC-3中的表达,并能提高细胞对化疗药物的敏感性。Objectives To observe the effect of MDRlsiRNA on drug sensitivity in pancreatic cancer cell line BxPC-3, and explore the new approach of improving chemotherapeutic effect in pancreatic cancer. Methods MDR1 siRNA recombinant plasmid was constructed by RNA interference technique, and then transfected into the pancreatic cancer cell BxPC-3 by liposome. Stable transfection cell clone was screened. RT-PCR and Western blot were used to detect the MDR1 mRNA and protein expression after RNA interference. Three kinds of cells （BxPC-3, BxPC-3/veetor, BxPC-3/ MDRlsiRNA） were injected subcutaneously to nude mice, which were observed for drug sensitivity to Gemeitabine. Results RT- PCR and Western blot showed that the MDR1 mRNA and protein expression in the BxPC-3/MDRlsiRNA group was significantly lower than the BxPC-3 and BxPC-3/vector groups.In vivo, the transplanted tumor of BxPC-3/MDRlsiRNA group was more sensitive to Gemcitabine （P〈0.05）. Conclusions The MDR1 siRNA recombinant plasmid can decrease MDR1 expression and improve ehemotherapeutics sensitivity in human pancreatic cancer cell line BxPC-3.

关 键 词：胰腺肿瘤 化学疗法 辅助 多药耐药基因1 糖蛋白类 

分 类 号：R735.9[医药卫生—肿瘤]